The specific features of Guillain–Barré syndrome in Russia: Analysis of 186 cases

The medical records of 186 patients diagnosed with Guillain-Barré syndrome (GBS) who had been followed up at the Research Center of Neurology, Russian Academy of Medical Sciences, in 2000 to 2011 were retrospectively analyzed. Most (65 %) of the patients had severe GBS; 19 % of the patients were on mechanical ventilation (MV) for an average of 21 (13; 48) days. The forms of GBS, such as acute inflammatory demyelinating polyneuropathy (AIDP) (n = 141; 78 %), and axonal variants, such as acute motor axonal neuropathy (AMAN), acute sensorimotor axonal neuropathy (AMSAN), i. e. AMAN / AMSAN (n = 39; 22 %), were studied separately. There was a significant difference in the seasonal revalence (p < 0.05). AIDP was encountered evenly throughout the year; AMAN / AMSAN occurred in 46 % of cases in summer. AIDP was followed by acute respiratory viral infection in 35 % of cases; diarrhea was
by the axonal forms in 36 % (p < 0.05). The axonal forms ran a severer course than AIDP: MV was performed twice more frequently (33 and 15 %, respectively); its duration was 6‑fold longer: 90 (46; 102) and 15 (10; 21) days (p < 0.05). AMAN / AMSAN was characterized by a severer neurological status and disability in the acute period, as shown by the NIS, MRCss, INCAT, R-ODS, and Barthel scales; these patients showed a poorer response to pathogenetic therapy (p < 0.05): 59 % with an insufficient effect; 15 % of those with AIDP. After six years, the majority (84 %) of the patients with AIDP walked alone and only 16 % were assisted. In the same period, less than half of the patients (40 %) with AMAN / AMSAN walked alone and a third (29 %) could move with assistance and almost the same percentage (31 %) could not walk.
Thus, a number of specific features of GBS were found in a Russian population (equal age and sex distribution; a larger percentage of the axonal forms than in European countries and the United States); however, the most characteristics did not differ from the global data.

1. Пирадов М.А. Синдром Гийена–Барре. М.: Интермедика, 2003. 240 с.

2. Супонева Н.А., Пирадов М.А., Никитин С.С., Алферова В.П. Острый гипокалиемический паралич вследствие передозировки препарата, содержащего корень солодки. Анн клин и экспер неврол 2008;1(2):47–51.

3. Pithadia А.B., Kakadia N. Guillain–Barré syndrome (GBS). Pharmacological Reports 2010;62:220–32.

4. McGrogan A., Madle G.C., Seaman H.E., de Vries C.S. The epidemiology of Guillain– Barré syndrome worldwide. A systematic literature review. Neuroepidemiology 2009;32(2):150–63.

5. Sejvar J.J., Baughman A.L., Wise M. Morgan O.W. Population incidence of Guillain–Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011;36(2):123–33.

6. van Doorn P.A., Ruts L., Jacobs B.C. Clinical features, pathogenesis, and treatment of Guillain–Barré syndrome. Lancet Neurol 2008;7(10):939–50.

7. Супонева Н.А., Пирадов М.А., Гнедовская Е.В. и др. Синдром Гийена–Барре: анализ оказания диагностической и лечебной помощи пациентам. Журн неврол и психиатр 2013;4:45–9.

8. Hughes R.A., Cornblath D.R. Gullain–Barré syndrome. Lancet 2005;366:1653–66.

9. Супонева Н.А., Пирадов М.А.,Никитин С.С. и др. Патогенетическая и прогностическая роль аутоантител к гликозидам периферических нервов при синдроме Гийена–Барре. Анн неврол 2013;7(1):4–11.

10. Ho T.W., Mishu B., Li C.Y. Gullain–Barré syndrome in Nothern China. Relaitionship to Campylobacter Jejuni infection and antiglycolipid antibodies. Brain 1995;118:597–605.

11. Yuki N. Carbohydrate mimicry: a new paradigm of autoimmune disease. Curr Opin Immunol 2005;17:577–82.

12. Lehmann H.C., Hartung H.P., Kieseier B.C. Hughes R.A. Guillain–Barré syndrome after exposure to influenza virus. Lancet Infect Dis 2010;10(9):643–51.

13. Yuki N., Hartung H.-P. Guillain–Barré syndrome. N Engl J Med 2012;366:2294– 304.

14. Baig F., Knopp M., Rajabally Y.A. Diagnosis, epidemiology and treatment of inflammatory neuropathies. Br J Hosp Med (Lond) 2012;3(7):80–5.

15. Feasby T.E., Gilbert J.J., Brown W.F. et al. An acute axonal form of Guillain– Barré polyneuropathy. Brain 1986;109 (Pt 6):1115–26.

16. Wee A.S., Abernathy S.D. The sural sensory nerve is usually spared in Guillain– Barré syndrome. J Miss State Med Assoc 2003;44:251–55.

17. Ye Y., Wang K., Deng F., Xing Y. Electrophysiological subtypes and prognosis of Guillain–Barré syndrome in Northeastern China. Muscle & Nerve 2013;47(1):68–71.

18. Hadden R.D., Cornblath D.R., Hughes R.A. et al. Electrophysiological classification of Guillain–Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain–Barré Syndrome Trial Group. Ann Neurol 1998;44(5):780–8.

19. John J. Grading of muscle power: comparison of MRC and analogue scales by physiotherapists. Medical Research Council. Int J Rehabil Res 1984;7(2):173–81.

20. Mahoney F.I., Barthel D.W. Functional Evaluation: The Barthel Index. Md State Med J 1965;14:61–5.

21. van Nes S.I., Vanhoutte E.K., van Doorn P.A. et al. Rasch-built Overall Disability Scale (R-ODS) for immunemediated peripheral neuropathies. Neurology 2011;76(4):337–45.

22. Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М.: Медиасфера, 2002.

23. Rajabally Y.A., Uncini A. Outcome and its predictors in Guillain–Barre syndrome. J Neurol Neurosurg Psychiatry 2012;83(7):711–8.

24. van Konigsveld R., van Doorn P.A., Shmitz P.I. et al. Mild forms of Gullain–Barré syndrome in an epidemiologic survey in The Netherlands. Neurology 2000;54:620–25.

25. Koga M., Yuki N., Hirata K. Antecedent symptoms of Guillain–Barré syndrome: an important indicator for clinical and serological subgroupes. Acta Neurol Scand 2001;103:278–87.

26. Uncini A., Manzoli C., Notturno F. et al. Pitfalls in electrodiagnosis of Guillain-Barre syndrome subtypes. J Neurol Neurosurg Psychiatry 2010;81:1157–63.

27. Hughes R.A.C., Swan A.V., Raphaёl J.S. et al. Immunotherapy for Gullain-Barré syndrome: a systematic review. Brain 2007;130:2245–57.

28. Пирадов М.А., Городецкий В.М., Рябинкина Ю.В. и др. Профилактика венозных тромбоэмболических осложнений и гепарин-индуцированная тромбоцитопения у больных с острой воспалительной полиневропатией (синдром Гийена–Барре). Анн клин и экспер неврол 2012;1(6):41–6.

29. Hughes R.A., Pritchard J., Hadden R.D. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Gullain–Barré syndrome. Cochrane Database Syst Rev 2011;3(CD008630).

30. Kuwabara S., Ogawara K., Misawa S. et al. Sensory nerve conduction in demyelinating and axonal Guillain–Barre syndromes. Eur Neurol 2004;51(4):196–8.

31. Ho T.W., Li C.Y., Cornblath D.R. et al. Patterns of recovery in the Guillain–Barré syndromes. Neurology 1997;48(3):695–700.

32. Kuwabara S., Mori M., Ogawara K. et al. Indicators of rapid clinical recovery in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 2001;70(4):560–2.

33. Uncini A.,Yuki N. Electrophysiologic and immunopathologic correlates in Guillain- Barré syndrome subtypes. Expert Rev Neurother 2009;9(6):869–84.

34. Baker M.G., Kvalsvig A., Zhang J. et al. Declining Guillain–Barre syndrome after campylobacteriosis control, New Zealand, 1988–2010. Emerg Infect Dis 2012;18(2):226–33.

35. Koga M., Takahashi M., Masuda M. Campylobacter gene polymorphism as a determinant of clinical features of Guillain–Barré syndrome. Neurology 2005;65:1376–81.

36. Susuki K., Rasband M.N., Tohyama K. et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 2007;27(15):3956–67.

37. Yuki N., Susuki K., Koga M. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain–Barré syndrome. Proc Natl Acad Sci USA 2004;101:11404–9.

38. Nachamkin I., Allos B.M., Ho T. Campylobacter species and Guillain-Barré syndrome. Clin Microbiol Rev 1998;11(3):555–67.

39. Yuki N. Guillain–Barré syndrome and anti-ganglioside antibodies: a clinicianscientist’s journey. Proc Jpn Acad Ser B Phys Biol Sci 2012;88(7):299–326.

40. Kuwabara S. Does Campylobacter jejuni infection elicit axonal or demyelinating Guillain–Barré syndrome, or both? J Neurol Neurosurg Psychiatry 2011;82(3):238.

41. Прудникова В.Д., Александрова В.В., Токарева Л.А. и др. Клинико-лабораторная характеристика кампилобактериоза в Липецкой области. 2005. Материалы 18-й Межрегиональной НПК «Актуальные вопросы повышения эффективности здравоохранения». Липецк, 2005.